Biologics in rheumatoid arthritis (RA) – recommendations for Swiss practice

Abstract

The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current “best practice” in Switzerland.

Keywords

• anti-TNF therapy
• biologics
• Guidelines
• Rheumatoid arthritisbiologicsanti-TNFtreatment optimizationguidelines
• treatment optimisation